Standards of treatment in chronic hepatitis C

Seminars in Liver Disease

Volumn 19, Issue 1 SUPPL. 1, 1999, Pages 35-48

  Gish, Robert G ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis C; Interferon alpha; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; ALPHAN1 INTERFERON; CONSENSUS INTERFERON; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

FIBROSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; LIVER CIRRHOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; REVIEW; VACCINATION; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 0032895973     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (187)

1. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244: 359-362
3. Mansell CJ, Locarnini SA. Epidemiology of hepatitis C in the East. Semin Liver Dis 1995;15:15-32
4. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499
5. McHutchison JG, Gordon SC, Eugene R, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
6. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352: 1426-1432
7. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(suppl 1):62S-65S
8. Alter MJ, Sampliner RE. Hepatitis C: and miles to go before we sleep. N Engl J Med 1989;321:1538-1540
9. National Institutes of Health. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26(suppl 1):2S-10S
10. Alter MJ. The epidemiology of acute and chronic hepatitis C. In: Davis GL, ed. Clinics in Liver Disease. Philadelphia: WB Saunders Co; 1997;1:559-568
11. Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology 1997;26:521-526
12. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993;88:240-243
13. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-974
14. Mattsson L, Weiland O, Glaumann H. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome. Liver 1988;8:184-188
15. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-281
16. Mattsson L, Weiland O, Glaumann H. Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up - a comparison. Liver 1989;9:120-127
17. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340
18. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998;27:1730-1735
19. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911
20. Koretz RL, Stone O, Mousa M, Gitnick GL. Non-A, non-B post-transfusion hepatitis - a decade later. Gastroenterology 1985;88: 1251-1254
21. Rao KV, Andersen RC. Long-term results and complications in renal transplant recipients. Observations in the second decade. Transplantation 1988;45:45-52
22. Kirkman RL, Strom TB, Weir MR, Tilney NL. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982;34:347-351
23. Grotz WH, Peters TH, Schlayer HJ, et al. Immunosuppressive therapy and hepatitis C virus infection: the clinical course of liver disease. J Mol Med 1996;74:407-412
24. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-147
25. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055
26. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-1440
27. Sugiura N, Sakai Y, Ebara M, et al. Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: clinical study of 26 cases. J Gastroenterol Hepatol 1996;11:535-539
28. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27:1394-1402
29. Kuwana K, Ichida T, Kamimura T, et al. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients. J Gastroenterol Hepatol 1997;12:149-155
30. Benvegnu L, Alberti A. Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig Dis Sci 1996;41(suppl 12):49S-55S
31. Camma C, Di Marco V, Lo Iacono O, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998;28:531-537
32. Lok AS. Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma? Hepatology 1995;22:1336-1338
33. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997;27:201-205
34. Tamori A, Kuroki T, Nishiguchi S, et al. Case of small hepatocellular carcinoma in the caudate lobe detected after interferon caused disappearance of hepatitis C virus. Hepatogastroenterology 1996;43:1079-1083
35. Makita F, Saitou S, Matsumoto T, et al. [Hepatocellular carcinoma following interferon therapy]. Nippon Shokakibyo Gakkai Zasshi 1996;93:406-410
36. Grimm I, Shaheen N. Can interferon prevent hepatocellular carcinoma in hepatitis C virus-induced cirrhosis? Gastroenterology 1996;110:2019-2021
37. Harper SE, Dienstag JL. Can interferon alfa treatment prevent hepatocellular carcinoma in patients with chronic hepatitis C infection and compensated cirrhosis? Hepatology 1996;23:930-933
38. Hirashima N, Mizokami M, Orito E, et al. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha. J Gastroenterol Hepatol 1996;11:955-958
39. Purcell R. The hepatitis C virus: overview. Hepatology 1997;26 (suppl 1):11S-14S
40. Manabe S, Fuke I, Tanishita O, et al. Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3. Virology 1994;198:636-644
41. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997;25:1527-1538
42. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63
43. Poynard T, Leroy V. Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-789
44. Heathcote EJ, Keeffe EB, Lee SS, et al. retreatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27: 1136-1143
45. Bresters D, Mauser-Bunschoten EP, Cuypers HT, et al. Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in hemophilia patients. Scand J Gastroenterol 1992;27:166-168
46. Carreno V, Tapia L, Ryff JC, Quiroga JA, Castillo I. Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha. J Med Virol 1992;37:215-219
47. Ferenci P, Vogel W, Pristautz H, et al. One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b. J Hepatol 1990;11(suppl 1):S50-S53
48. Iino S. High dose interferon treatment in chronic hepatitis C. Gut 1993;34(suppl2):S114-S118
49. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231
50. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee. Lancet 1997;349:1086-1092
51. Katzenstein DA. Antiretroviral therapy for human immunodeficiency virus infection in 1997. West J Med 1997;166:319-325
52. Acero D, Adrados M, Gonzalez-Huix F, Figa M. [Ribavirin treatment in patients with chronic hepatitis C refractory to interferon-alpha]. Gastroenterol Hepatol 1996;19:243-246
53. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473-477
54. Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993;19:408-412
55. Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16: 649-654
56. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903
57. White DO. Antiviral chemotherapy. Med J Aust 1984; 140:715-720
58. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alpha for alpha-interferon resistant chronic hepatitis C. Gastroenterology 1994;107:812-817
59. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312
60. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997;26(suppl 1): 108S-111S
61. Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology 1994;19:280-285
62. Reichard O, Glaumann H, Fryden A. et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995;21:918-922
63. Schalm SW, Brouwer JT, Chemello L. et al. Interferon-ribavirin combination therapy for chronic hepatitis C. Dig Dis Sci 1996; 41(suppl 12):131S-134S
64. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C Meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-966
65. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995;46:43-47
66. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993;38:612-618
67. Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Hepatology 1997;26(suppl 1):101S-107S
68. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: retreatment with alpha interferon. Hepatology 1997;26(suppl 1):137S-142S
69. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997;26(suppl 1):71S-77S
70. Schalm SW, Brouwer JT. Antiviral therapy of hepatitis C. Scand J Gastroenterol Suppl 1997;223:46-49
71. Brass CA. Efficacy of interferon monotherapy in the treatment of relapsers and nonresponders with chronic hepatitis C infection. Clin Ther 1998;20:388-397
72. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881
73. Lau JY, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 1993;342:1208-1209
74. Magrin S, Craxi A, Fabiano C, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology 1994;19:273-279
75. Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351-1354
76. Picciotto A, Campo N, Brizzolara R, et al. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy. Eur J Gastroenterol Hepatol 1997;9:67-69
77. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994;330:744-750
78. Mizokami M, Gojobori T, Lau JY. Molecular evolutionary virology: its application to hepatitis C virus. Gastroenterology 1994;107:1181-1182
79. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26:122S-127S
80. Marcellin P, Boyer N, Behamou JP, Erlinger S. Interferon-alpha therapy for chronic hepatitis C in special patient populations. Dig Dis Sci 1996;41(suppl 12):126S-130S
81. Kobayashi Y, Watanabe S, Konishi M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 1993; 18:1319-1325
82. Volmer J, Luders CJ, Henning H. Semiquantitative and morphometric investigations on the histopathology of chronic hepatitis non-A, non-B. Z Gastroenterol 1985;23:632-642
83. Fevery J, De Groote J, Desmet V, et al. Long-term follow-up of mild chronic active hepatitis. Acta Gastroenterol Belg 1987; 50:341-352
84. Kryger P, Christoffersen P, Aldershvile J, Mathiesen LR, Nielsen JO, Tage-Jensen U. The long-term prognosis of non-transfusion-associated non-A, non-B hepatitis. A clinical, epidemiological, and histological investigation. Scand J Gastroenterol 1983; 18:519-527
85. Czaja AJ, Taswell HF, Rakela J, Schimek CM. Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. Mayo Clin Proc 1991;66:572-582
86. Manabe N, Chevallier M, Chossegros P, et al. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993; 18:1344-1349
87. Lampertico P, Rumi M, Romeo R, et al. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22
88. Vogel W, Graziadei I, Umlauft F, et al. High-dose interferon-alpha 2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996;41(suppl 12):81S-85S
89. Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MUL-TIVIRC Group. Hepatology 1998;27:1213-1219
90. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997;26(suppl 1):133S-136S
91. Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-1257
92. Shakil AO. Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330-337
93. Montalto G, Zignego AL, Ruggeri MI, et al. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases. Dig Dis Sci 1997;42:1703-1707
94. Prieto M, Olaso V, Verdu C, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995;22:413-417
95. Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbara L. Persistent hepatitis C viraemia without liver disease. Lancet 1993;341:464-465
96. Alberti A, Morsica G, Chemello L, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697-698
97. Chan TM, Lok AS, Cheng IK, Chan RT. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 1993;104:862-868
98. Cheung RC, Chan RT, Lok AS. Longitudinal study of hepatitis C viremia in chronic hepatitis C. J Med Virol 1993;41:338-342
99. Yuki N, Hayashi N, Takehara T, et al. Serum hepatitis C virus RNA levels and liver injury in volunteer blood donors. Am J Gastroenterol 1994;89:1462-1466
100. Naito M, Hayashi N, Hagiwara H, et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994; 19:871-875
101. Salmeron FJ, Palacios A, Perez-Ruiz M, et al. Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors. Dig Dis Sci 1996;41:1933-1938
102. Everhart JE, Stolar M, Hoofnagle JH. Management of hepatitis C: a national survey of gastroenterologists and hepatologists. Hepatology 1997;26(suppl 1):78S-82S
103. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995;15:64-69
104. Ilyin GP, Langouet S, Rissel M, Delcros JG, Guillouzo A, Guguen-Guillouzo C. Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes. Hepatology 1998;27:1687-1694
105. Czaja AJ. Extrahepatic immunologic features of chronic viral hepatitis. Dig Dis Sci 1997;15:125-144
106. Marcellin P, Benhamou JP. Autoimmune disorders associated with hepatitis C. Prog Liver Dis 1995;13:247-267
107. Bloch KJ. Cryoglobulinemia and hepatitis C virus. N Engl J Med 1992;327:1521-1522
108. Gordon SC. Extrahepatic manifestations of hepatitis C. Dig Dis Sci 1996;14:157-168
109. Casato M, Lagana B, Pucillo LP, Quinti I. Interferon for hepatitis C virus-negative type II mixed cryoglobulinemia. N Engl J Med 1998;338:1386-1387
110. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-756
111. Safadi R, Ilan Y, Ashur Y, Shouval D. Hepatitis C-associated cryoglobulinemia presenting with pericardial effusion. Am J Gastroenterol 1997;92:710-712
112. Sharara AI. Chronic hepatitis C. South Med J 1997;90:872-877
113. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-354
114. Koike K, Kobayashi M, Gondo M, Hayashi I, Osuga T, Takada S. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998;54:249-255
115. Pouteil-Noble C, Tardy JC, Chossegros P, et al. Co-infection by hepatitis B virus and hepatitis C virus in renal transplantation: morbidity and mortality in 1098 patients. Nephrol Dial Transplant 1995;10(suppl 6):122-124
116. Pouteil-Noble C, Maiza H, Donia A, et al. Comparison of isolated infection by hepatitis C (HCV) or by hepatitis B (HBV) viruses and of co-infection by HCV-HBV in 1098 renal transplant patients. Transplant Proc 1997;29:791-792
117. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485-490
118. Serfaty L, Chazouilleres O, Poujol-Robert A, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology 1997;26:776-779
119. Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology 1994;20:1152-1155
120. Beld M, Penning M, Lukashov V, et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 1998;244:504-512
121. Berger A, von Depka Prondzinski M, Doerr HW, Rabenau H, Weber B. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV co-infection. J Med Virol 1996; 48:339-343
122. Diamondsstone LS, Blakley SA, Rice JC, Clark RA, Goedert JJ. Prognostic factors for all-cause mortality among hemophiliacs infected with human immunodeficiency virus. Am J Epidemiol 1995;142:304-313
123. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Co-infection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995;172:1503-1508
124. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol 1997;92: 1130-1134
125. Ghany MG, Leissinger C, Lagier R, Sanchez-Pescador R, Lok AS. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis Sci 1996;41: 1265-1272
126. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5
127. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-695
128. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994;84:1020-1023
129. Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JL. Rapidly progressive non-A. non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989;97:1559-1561
130. Chamot E, Hirschel B, Wintsch J, et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS 1990;4:1275-1277
131. Boyer N, Marcellin P, Degon C, et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992;165:723-726
132. Marriott E, Navas S, del Romero J, et al. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV positive patients. J Med Virol 1993;40:107-111
133. Davis GL. Interferon treatment of viral hepatitis in immunocompromised patients. Semin Liver Dis 1989;9:267-272
134. Hsu HH, Wright TL, Tsao SC, et al. Antibody response to hepatitis C virus infection after liver transplantation. Am J Gastroenterol 1994;89:1169-1174
135. Maple PA, McKee T, Desselberger U, Wreghitt TG. Hepatitis C virus infections in transplant patients: serological and virological investigations. J Med Virol 1994;44:43-48
136. Sanchez-Tapias JM, Rodes J. Dilemmas of organ transplantation from anti-HCV-positive donors. Lancet 1995;345:469-470
137. Pirsch JD, Belzer FO. Transmission of HCV by organ transplantation. N Engl J Med 1992;326:412-413
138. Lau JY, Davis GL, Brunson ME, et al. Hepatitis C virus infection in kidney transplant recipients [published erratum appears in Hepatology 1994;19:1329]. Hepatology 1993;18:1027-1031
139. Pol S, Legendre C, Saltiel C, et al. Hepatitis C virus in kidney recipients. Epidemiology and impact on renal transplantation. J Hepatol 1992;15:202-206
140. Ponz E, Campistol JM, Bruguera M, et al. Hepatitis C virus infection among kidney transplant recipients. Kidney Int 1991; 40:748-751
141. Rohr MS, Lesniewski RR, Rubin CA, et al. Risk of liver disease in HCV-seropositive kidney transplant recipients. Ann Surg 1993;217:512-517
142. Wright TL. Liver transplantation for chronic hepatitis C viral infection. Gastroenterol Clin North Am 1993;22:231-242
143. McCruden EA, Welch S, Batchelor B, et al. Hepatitis C virus infection detected by antibody tests and the polymerase chain reaction as a cause of liver dysfunction in renal transplant recipients. J Med Virol 1994;42:158-163
144. Goffin E, Pirson Y, Cornu C, Geubel A, Squifflet JP, van Ypersele de Strihou C. Outcome of HCV infection after renal transplantation. Kidney Int 1994;45:551-555
145. Gladziwa U, Schlipkoter U, Lorbeer B, Cholmakow K, Roggendorf M, Sieberth HG. Prevalence of antibodies to hepatitis C virus in patients on peritoneal dialysis - a multicenter study. Clin Nephrol 1993;40:46-52
146. Huang CC. Hepatitis in patients with end-stage renal disease. J Gastroenterol Hepatol 1997;12:S236-S241
147. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981-999
148. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998;53:1374-1381
149. Kazi S, Prasad S, Pollak R, et al. Hepatitis C infection in potential recipients with normal liver biochemistry does not preclude renal transplantation. Dig Dis Sci 1994;39:961-964
150. Kliem V, van den Hoff U, Brunkhorst R, et al. The long-term course of hepatitis C after kidney transplantation. Transplantation 1996;62:1417-1421
151. Durlik M, Gaciong Z, Soluch L, etal. Effect of chronic liver disease on clinical outcome in renal allograft recipients. Transplant Proc 1997;29:787-790
152. Haem J, Berthoux P, Mosnier JF, et al. Clear evidence of the existence of healthy carriers of hepatitis C virus among renal transplant recipients. Transplantation 1996;62:699-700
153. Rao KV, Ma J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 1996;62:1765-1769
154. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29:608-614
155. Duarte R, Huraib S, Said R, et al. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis 1995;25:40-45
156. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998;66:471-476
157. Rodrigues A, Morgado T, Areias J, et al. Limited benefits of INF-alpha therapy in renal graft candidates with chronic viral hepatitis B or C. Transplant Proc 1997;29:777-780
158. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995;59: 1426-1431
159. Ozdogan M, Ozgur O, Gur G, et al. Histopathological impacts of hepatitis virus infection in hemodialysis patients: should liver biopsy be performed before renal transplantation? Artif Organs 1997;21:355-358
160. Goral S, Helderman JH. Hepatitis C and renal transplantation: the controversy continues. Kidney Int 1998;53:1419-1420
161. Goffin E, Pirson Y, van Ypersele de Strihou C. Implications of chronic hepatitis B or hepatitis C infection for renal transplant candidates. Nephrol Dial Transplant 1995;10(suppl 6): 88-92
162. Terrault NA, Wright TL, Pereira BJ. Hepatitis C infection in the transplant recipient. Infect Dis Clin North Am 1995;9:943-964
163. Lim HL, Lau GK, Davis GL, Dolson DJ, Lau JY. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology 1994;106: 248-251
164. Schoeman MN, Liddle C, Bilous M, et al. Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity, and effects of immunosuppressive therapy on disease progression. Aust NZJ Med 1990;20:56-62
165. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322
166. Bizollon T. Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26: 500-504
167. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27: 1403-1407
168. Ni YH, Lin HH, Chen PJ, Hsu HY, Chen DS, Chang MH. Temporal profile of hepatitis C virus antibody and genome in infants born to mothers infected with hepatitis C virus but without human immunodeficiency virus co-infection. J Hepatol 1994;20:641-645
169. Novati R, Thiers V, Monforte AD, et al. Mother-to-child transmission of hepatitis C virus detected by nested polymerase chain reaction. J Infect Dis 1992;165:720-723
170. Grange JD, Abergel A, Amiot X, et al. [Interactions between chronic viral hepatitis C and pregnancy]. Gastroenterol Clin Biol 1995;19:520-524
171. Reinus JF, Leikin EL, Alter HJ, et al. Failure to detect vertical transmission of hepatitis C virus. Ann Intern Med 1992; 117:881-886
172. Roudot-Thoraval F, Pawlotsky JM, Thiers V, et al. Lack of mother-to-infant transmission of hepatitis C virus in human immunodeficiency virus-seronegative women: a prospective study with hepatitis C virus RNA testing. Hepatology 1993;17: 772-777
173. Bortolotti F, Resti M, Giacchino R, et al. Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus. J Pediatr 1997;130:990-993
174. Freitag-Koontz MJ. Prevention of hepatitis B and C transmission during pregnancy and the first year of life. J Perinat Neonatal Nurs 1996;10:40-55
175. Lutwick LI. Postexposure prophylaxis. Infect Dis Clin North Am 1996;10:899-915
176. Tedder RS, Gilson RJ, Briggs M, et al. Hepatitis C virus: evidence for sexual transmission. BMJ 1991;302:1299-1302
177. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995;345:1209-1211
178. Gish RG, Qian KP, Quan S, et al. Concordance between hepatitis C virus serotyping assays. J Viral Hepat 1997;4:421-422
179. Piazza M, Sagliocca L, Tosone G, et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 1997;157:1537-1544
180. Tassopoulos NC, Papaevangelou GJ, Roumeliotou-Karayannis A, et al. Fulminant hepatitis in asymptomatic hepatitis B surface antigen carriers in Greece. J Med Virol 1986;20:371-379
181. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-2113
182. De Sousa M. T lymphocytes and iron overload: novel correlations of possible significance to the biology of the immunological system. Mem Inst Oswaldo Cruz 1992;87(suppl 5):23-29
183. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994;89:986-988
184. Smith BC, Gorve J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699
185. Clemente MG, Congia M, Lai ME, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994;125:123-128
186. Perez R, Pravia R, Linares A, et al. Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C. Gut 1993;34(2 suppl):S139-S140
187. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994;20:410-415